Compare Ascendis Pharma A/S (ASND) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Gold Fields Limited — how do they compare? Ascendis Pharma A/S trades at $256.72 (market cap $16.67B), while Gold Fields Limited trades at $41.08 (market cap $36.07B). The key difference: Gold Fields Limited is far larger — about 2.2× Ascendis Pharma A/S's market cap, and Gold Fields Limited pays a 5.76% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | GFI | |
|---|---|---|
Market Cap | $16.67B | $36.07B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $61.52 |
52-Week Low | $189.74 | $29.31 |
Enterprise Value | $17.04B | $37.51B |
Dividend Yield | — | 5.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Gold Fields Limited (GFI) trades at $41.12, up 0.73% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 40.76% net income margin and ROE of 52.33%, though recent quarterly earnings missed expectations. Revenue grew to $5.2B in 2024, with net income reaching $1.25B. Analyst consensus is a Buy with a $52 price target, indicating 26% upside potential.
The outlook for GFI is positive given its robust fundamentals and gold price tailwinds, but risks include volatile earnings performance and rising debt levels. Institutional accumulation and favorable sector sentiment support the bullish case, though investors should monitor cost pressures and execution on growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
